INmune Bio (INMB)
(Delayed Data from NSDQ)
$10.85 USD
-0.32 (-2.86%)
Updated May 17, 2024 04:00 PM ET
After-Market: $10.85 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
INMB 10.85 -0.32(-2.86%)
Will INMB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for INMB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INMB
Wall Street Analysts Predict a 99% Upside in INmune Bio, Inc. (INMB): Here's What You Should Know
Can INmune Bio, Inc. (INMB) Climb 105% to Reach the Level Wall Street Analysts Expect?
INMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Analysts Initiate Coverage: 5 Stocks for Higher Returns
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study
Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates
Other News for INMB
Inmune Bio Inc Grants Stock Options to Top Executives
Analysts Offer Insights on Healthcare Companies: Inmune Bio (INMB), Insmed (INSM) and Tenet Healthcare (THC)
Robust Pipeline and Financial Stability Underpin Buy Rating for Inmune Bio
INmune Bio, Inc. (INMB) Q1 2024 Earnings Call Transcript
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update